NCT07042828View on ClinicalTrials.gov

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 16, 2025

Study Completion Date

June 19, 2025

Conditions
Allergic Rhino-ConjunctivitisUrticaria
Interventions
DRUG

Bilastine oral dispersible tablets

Bilastine 20 mg oral dispersible tablets

DRUG

Bilaxten oral dispersible tablets

Bilaxten 20 mg oral dispersible tablets

Trial Locations (1)

380 051

Veeda Clinical Research Ltd., Ahmedabad

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY